VR Adviser
OLMA icon

VR Adviser’s Olema Pharmaceuticals OLMA Stock Holding History

VR Adviser’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-77,042
Closed -$872K – 43
2024
Q1 		$872K Hold
77,042
– – 0.04% 38
2023
Q4 		$1.08M Hold
77,042
– – 0.07% 36
2023
Q3 		$951K Buy
+77,042
New +$785K 0.1% 35
2022
Q1 		– Sell
-816,651
Closed -$7.64M – 31
2021
Q4 		$7.64M Sell
816,651
-719,542
-47% -$14.9M 1.04% 22
2021
Q3 		$42.3M Hold
1,536,193
– – 5.44% 7
2021
Q2 		$43M Hold
1,536,193
– – 5.21% 7
2021
Q1 		$51M Hold
1,536,193
– – 5.53% 4
2020
Q4 		$73.9M Buy
+1,536,193
New +$72M 10.86% 2

Other funds holding OLMA

BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MPM BioImpact
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

VR Adviser's OLMA Position: Q2 2024 in Review

VR Adviser sold out of Olema Pharmaceuticals (OLMA) in Q2 2024, closing a stake of 77,042 shares — an estimated $872K sold.

VR Adviser first reported a position in OLMA in Q4 2020 and held it in 8 quarters. The position peaked at $73.9M in Q4 2020. 129 funds tracked by Wall St. Rank hold OLMA as of Q2 2024.

  • VR Adviser reported no remaining Olema Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • VR Adviser sold 77,042 Olema Pharmaceuticals shares in Q2 2024, an estimated $872K.
  • VR Adviser first reported a position in Olema Pharmaceuticals in Q4 2020 and held it in 8 quarters.
  • VR Adviser's Olema Pharmaceuticals position peaked at $73.9M in Q4 2020.
  • 129 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2024.

Based on VR Adviser's 13F filing for Q2 2024, filed 14 Aug 2024.